Adapting Biopharma Launches in the COVID-19 LandscapeByBen Hohn,Judith KulichApril 7th 2020Judith Kulich and Ben Hohn pose the high priority questions that those teams opting to move forward with a launch, or to move forward after a delay, in the face of the COVID-19 pandemic.
Is the Tail Wagging the Dog in Drug Market Entry?ByJudith Kulich,Ben HohnJanuary 13th 2020Pharmaceutical ExecutiveThree product launch trends driven by emerging biopharma.